William Blair analyst Sami Corwin maintained a Buy rating on Applied Therapeutics (APLT – Research Report) today. The company’s ...
Fintel on MSN5d
William Blair Initiates Coverage of Apellis Pharmaceuticals (APLS) with Outperform RecommendationFintel reports that on October 16, 2024, William Blair initiated coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) with a ...
William Blair lowered their Q1 2025 EPS estimates for Cantaloupe in a research report issued on Friday, October 18th. William ...
Equities research analysts at William Blair lowered their Q1 2025 earnings estimates for Wolfspeed in a report released on ...
RBC Capital analyst Sabahat Khan maintained a Hold rating on Waste Management (WM – Research Report) on October 18 and set a price target ...
Danaher posts Q3 sales of $5.79 billion, surpassing expectations. 2024 guidance includes bioprocessing revenue decline and Cepheid respiratory sales of $1.7 billion.
On Monday, Tarsus Pharmaceuticals Inc (TARS) stock saw a decline, ending the day at $36.45 which represents a decrease of $-0.17 or -0.46% from the prior close of $36.62. The stock opened at $36.56 ...
BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental ...
In addition to the transaction, Kevin Twomey, a partner at WestView, will join the CardFlight board of directors.
Starbucks (SBUX) has the money to tackle its staffing issues, according to William Blair analyst Sharon Zackfia. By investing ...
From the rugged rivers of Kamchatka in Russia to the unchartered waters of the Amazon and the untouched flats of the Bahamas, ...
William Blair最近对Baldwin Insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback